Literature DB >> 12631219

Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody.

Y Arai1, M Nishida.   

Abstract

We have previously reported that both endometrial cancer and endometrial hyperplasia stain positively for the anti-LeY monoclonal antibody, whereas normal endometrium does not. Endometrial hyperplasia is a premalignant change associated with the eventual development of endometrial carcinoma. However, it can be difficult to differentiate hyperplasia from normal endometrium in cytology. This study illustrates the use of immunocytochemical cytology using anti-LeY monoclonal antibody to differentiate between endometrial hyperplasia and normal endometrium. Immunostaining using anti-LeY monoclonal antibody was performed on cytologic specimens obtained from 17 normal endometria, 25 endometria with endometrial hyperplasia, and 13 endometria with endometrial carcinoma. All normal endometria displayed negative staining for anti-LeY monoclonal antibody, whereas all endometria with endometrial carcinoma displayed positive staining. Of the endometrial hyperplasia cases, 21 displayed positive staining. However, four displayed negative staining due to the small number of cells available for diagnosis. We believe that immunostaining cytology using anti-LeY monoclonal antibody is a useful method for differentiating between normal endometrium and endometrial hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631219     DOI: 10.1046/j.1525-1438.2003.13009.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  The expression of annexin II and Lewis y antigen in ovarian epithelial tumors and the correlation between them.

Authors:  Huiyu Zhuang; Mingzi Tan; Juanjuan Liu; Xiao Li; Jian Gao; Zhenhua Hu; Lu Deng; Liancheng Zhu; Bei Lin
Journal:  Tumour Biol       Date:  2014-11-22

2.  Blood group antigens SLeX, SLeA, and LeY as prognostic markers in endometrial cancer.

Authors:  Thomas Kolben; Lena Müller; Sarah Meister; Lucia Keilmann; Christina Buschmann; Fabian Trillsch; Alexander Burges; Bastian Czogalla; Sophie Mitter; Elisa Schmoeckel; Stefanie Corradini; Sven Mahner; Udo Jeschke; Mirjana Kessler; Susanne Beyer
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-21       Impact factor: 4.322

3.  Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis.

Authors:  Mingzi Tan; Liancheng Zhu; Huiyu Zhuang; Yingying Hao; Song Gao; Shuice Liu; Qing Liu; Dawo Liu; Juanjuan Liu; Bei Lin
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

4.  Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway.

Authors:  Juanjuan Liu; Bei Lin; Yingying Hao; Yue Qi; Liancheng Zhu; Feifei Li; Dawo Liu; Jianping Cong; Shulan Zhang; Masao Iwamori
Journal:  J Exp Clin Cancer Res       Date:  2009-12-15

5.  Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87.

Authors:  Sadayuki Kawai; Shunsuke Kato; Hiroo Imai; Yoshinari Okada; Chikashi Ishioka
Journal:  Oncol Rep       Date:  2012-11-01       Impact factor: 3.906

6.  Correlation analysis of human embryo LeY glycan antigen expression and embryo quality.

Authors:  Juan Gu; Linlin Sui; Yanni Ma; Zhenzhen Guo; Man Zhang; Chenyang Zhu; Zhu Cai; Ying Kong
Journal:  Exp Ther Med       Date:  2017-05-22       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.